Detalhe da pesquisa
1.
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Hematol Oncol
; 39(3): 409-418, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33590502
2.
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Blood
; 118(12): 3273-9, 2011 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21791425
3.
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
Cancers (Basel)
; 15(14)2023 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509367
4.
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Blood Cancer J
; 13(1): 65, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37137878
5.
Hematopoietic stem cell mobilization.
Haematologica
; 93(3): 321-4, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18310535
6.
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
J Clin Oncol
; 26(9): 1519-25, 2008 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18268357
7.
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Br J Haematol
; 139(3): 415-24, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17910631
8.
Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging.
Biol Blood Marrow Transplant
; 13(10): 1224-32, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17889360
9.
Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
Rev Bras Hematol Hemoter
; 33(3): 172-3, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-23049286
10.
Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
Rev. bras. hematol. hemoter
; 33(3): 172-173, June 2011.
Artigo
em Inglês
| LILACS | ID: lil-596312